NCT07534371 2026-04-16
Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study
West China Hospital
Active not recruiting
Clinical Trials
8 trialsNCT07357623 2026-01-22
Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors
Shanghai Chest Hospital
Phase 2 Recruiting
NCT07272512 2025-12-19
ZSPAC-17
Shanghai Zhongshan Hospital
Phase 4 Recruiting
NCT05165407 2025-03-14
NESSIE
Peking University
Phase 2 Recruiting
NCT05989425 2023-08-14
Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer
Fudan University
Phase 2 Recruiting
NCT05973968 2023-08-04
Surufatinib in G3 Neuroendocrine Tumors
Qilu Hospital of Shandong University
Unknown
NCT05747729 2023-02-28
A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2 Unknown
NCT05627427 2022-11-25
Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown